CNTB — Q2 2026 Financial Report Analysis

A one-off licence payment shrank the loss, but the spending is what matters

Connect Biopharma is a clinical-stage drug developer: it has no product on sale and earns money only from partners. Its single drug candidate, rademikibart, is an antibody that blocks the IL-4 receptor (the same target as Sanofi/Regeneron's Dupixent), and the company is testing it as an add-on treatment when patients with asthma or COPD (chronic obstructive pulmonary disease, a long-term lung disease often linked to smoking) suffer a sudden flare-up. For a company like this, the quarterly numbers come down to three questions: how much it spent, how much cash it has left, and how the trials are going.

In the second quarter of 2026 (April–June), the net loss widened to $17.3 million from $12.9 million a year earlier. Research and development (R&D) spending nearly doubled to $16.3 million because two mid-stage (Phase 2) trials were running at full speed. Revenue jumped to $2.8 million from $48,000, but that came from a single milestone payment from its Chinese partner, not from sales. Cash and short-term investments fell to $31.5 million at June 30, from $44.3 million at the end of 2025, even after a $20.2 million share sale in March.

At a glance

• $31.5 million in cash and short-term investments at June 30 — about two quarters of spending at the first half's pace ($31.9 million of operating cash used in six months), although management says it is enough for at least a year from August 12, 2026.
• R&D up 85% to $16.3 million — almost all of it rademikibart trial costs ($12.5 million vs $5.8 million), so the loss grew for the reason it was supposed to: the trials that produced results in September.
• The trial readouts after the quarter matter more than the quarter. The COPD study hit its main goal (81% fewer treatment failures than placebo, p=0.0122); the asthma study missed its main goal (p=0.153) but hit its key lung-function secondary goal (p=0.023).

The numbers

All figures in US dollars, three months ended June 30, from the company's Form 10-Q.

"n/m" means not meaningful: going from $48,000 to $2.8 million is a jump of several thousand percent that says nothing about the business. Operating margin (profit from operations as a share of revenue) is likewise not meaningful for a company whose revenue is a single partner payment, so it is left out.

For the first half (January–June), the net loss was $36.7 million vs $23.2 million a year earlier, and R&D was $31.3 million vs $15.4 million.

Where the money went

R&D. The filing breaks R&D into rademikibart costs ($12.5 million vs $5.8 million), personnel and other costs ($3.5 million vs $2.8 million) and share-based pay ($0.3 million, flat). The company says the increase was "primarily due to an increase in costs related to the development of rademikibart": both Phase 2 "Seabreeze STAT" trials — one in asthma, one in COPD — started in the second quarter of 2025 and completed enrollment by mid-2026. In August 2026 the company also started a third, smaller study (Seabreeze STAT IV, 40 patients) designed to bridge from a 600 mg injection under the skin to a 300 mg injection into a vein, a quicker route of delivery in an emergency setting.

General and administrative (G&A). Overhead fell 13% to $4.1 million. The filing attributes this to lower professional fees, because the 2025 quarter included one-time advisory costs tied to the company's move to become "more U.S.-centric" (it is incorporated in the Cayman Islands, has operations in China, and is now headquartered in San Diego).

Interest income halved to $0.3 million from $0.6 million, because there is simply less cash earning interest.

Where the revenue came from

All revenue comes from a 2023 licensing deal with Simcere Pharmaceutical, which holds the rights to rademikibart in mainland China, Hong Kong, Macau and Taiwan. In the second quarter, Simcere's progress triggered a regulatory milestone of about $7 million. But the company booked only $2.8 million of revenue, because about $4 million of shared development costs it owes Simcere is subtracted from revenue under the accounting rules (payments to a customer reduce the revenue from that customer).

Two details from the same note matter:

• A second milestone, worth about $4 million, lapsed in the quarter because it was not reached by its contractual deadline. A similar $8 million milestone lapsed in 2025. The total remaining milestones Connect can still earn from Simcere are now about $99 million, down from an initial $123 million, and depend on Simcere's own development and sales work.
• The money had not arrived yet. Accounts receivable (money owed to the company) rose to $2.9 million at June 30 from $13,000 at year-end, so the milestone helped the income statement but not yet the cash balance.

What the headline numbers hide

• The loss would have been larger without the milestone. Excluding the $2.8 million of net Simcere revenue, the second-quarter loss would have been roughly $20 million — closer to the first quarter's $19.4 million. The narrower-looking jump in the loss (34%) understates how much spending rose.
• Loss per share grew less than the loss itself because of new shares, not better results. The loss widened 34% but the loss per share widened only 17%, because the share count grew about 13% (weighted average 62.9 million vs 55.5 million) after the March private placement of 6.13 million shares at roughly $3.29 each. Each existing shareholder now owns a smaller slice of the company.
• Cash burn was flattered slightly by unpaid bills. Operating cash use ($31.9 million in six months) was a bit lower than the $36.7 million net loss partly because accrued liabilities (expenses incurred but not yet paid, such as trial-site invoices) rose $2.7 million and prepaid expenses fell $2.4 million. Those bills still have to be paid; the receivable from Simcere ($2.9 million) works the other way once collected.
• The one-year cash statement leans on a slowdown. At the first half's pace (about $16 million of operating cash a quarter), $31.5 million would last roughly two quarters. Management states the cash is enough for "at least one year" from the August 12 filing date, and the filing contains no "going concern" warning (the formal accounting caution that a company may run out of money within a year). Reconciling the two requires spending to fall sharply now that the two main trials are finished — plausible, since enrollment-driven trial costs drop once a study closes — but the filing does not quantify the planned cut.
• No other red flags in the filing: no debt, no material legal proceedings, controls reported effective, and no change to risk factors since the annual report.

Takeaway: This quarter's financials are a bridge to September's trial results, and those results were mixed in a useful way: a clear win in COPD and a miss on the main goal in asthma. With $31.5 million of cash and Phase 3 trials typically costing far more than that, the company will almost certainly need a partner or new shares before rademikibart can reach a final-stage study.

Trial results since the quarter ended

Both Seabreeze STAT readouts came in September 2026, after this quarter closed (8-K filings of September 15 and September 30):

A "p-value" below 0.05 is the usual bar for treating a result as unlikely to be chance. The company says the asthma study missed because fewer placebo patients failed treatment than it had projected, making a difference harder to prove in a 160-person study. In both studies the drug was well tolerated, with no new safety signals.

Outlook

Management plans to meet the US Food and Drug Administration (FDA) to agree on a Phase 3 program, using the readouts to choose the main goal and the number of patients needed. The things to watch over the next two quarters:

• Funding. A shelf registration (Form F-3) declared effective on June 1, 2026 lets the company sell new shares quickly. Given $31.5 million of cash at June 30 and the cost of a Phase 3 program, a share sale, a regional partnership outside China, or both is the most likely next step — each one dilutes existing holders or gives up part of the drug's future value.
• Spending in the third quarter. The 10-Q for July–September (expected around mid-November 2026, based on the May 12 and August 12 filing dates) will show whether R&D drops after the two main trials closed. That is the number that tests management's one-year cash statement.
• The FDA's response, especially whether it accepts lung function at week 1 as a Phase 3 main goal in asthma, where the treatment-failure goal missed.
• Simcere milestones (up to about $99 million remaining), which have already lapsed twice when deadlines were missed, so they should not be counted on.

Our read: the COPD result gives the company something to fund a Phase 3 around, but the balance sheet cannot carry one alone. The next filing's cash burn and any financing announcement will say more about the stock's near-term path than the trial data already disclosed.